We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Failure to Institute CAPA, MDR Procedures Draw Warning for Simpro

Failure to Institute CAPA, MDR Procedures Draw Warning for Simpro

October 7, 2016

Failure to establish corrective and preventive action procedures as well as procedures for receiving and reviewing complaints landed Texas-based Simpro an FDA warning letter.

Although the manufacturer of non-invasive blood pressure monitors, fingertip pulse oximeters and portable fetal dopplers committed to developing a process and procedure for malfunctioning and returned products, its response didn’t demonstrate that it had developed a method to review the circumstances surrounding returned products to determine whether or not a CAPA investigation was necessary, the Aug. 17 letter said.

Similarly, the firm committed to establish a written complaint form, but it hadn’t committed to establishing procedures for receiving, reviewing and evaluating complaints by a formally designated unit.

Complaint Investigations

Simpro’s response didn’t provide assurance that it had developed a method for reviewing the circumstances surrounding complaints it had received to determine if an investigation was needed. The letter noted that the firm also had not provided a date for establishing such procedures.

Moreover, the manufacturer didn’t have any written Medical Device Reporting procedures, the warning letter said, and it didn’t provide adequate detail in its response about when it would establish MDR procedures or that it had reviewed complaints to see if they were reportable.

The letter noted that a follow-up inspection may be required to verify that the corrections have been implemented.

In addition, FDA inspectors reviewed Simpro’s website and found some of the language describing the products to be misleading, causing the company’s products to be misbranded.

For example, the firm said its portable fetal doppler was “FDA approved,” but the agency said that language was misleading because the device didn’t go through the premarket approval process. The agency asked the company to provide evidence that it did go through the PMA process or to remove the “FDA approved” reference from marketing materials.

In another example, the firm refers to its oximeters on its website as “not a medical device,” but Simpro lists the products with FDA as Class II devices. The agency requested an explanation for the discrepancy.

Medical device manufacturers often dread the FDA inspector’s arrival. But here’s a shortcut to success you can master in an hour or so. Troubleshooting Your Quality System will address the five most common problem areas: corrective and preventive action, complaint handling, medical device reporting, purchasing controls and process validation.

View today's stories

Medical Devices Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • UKflag.jpg

    UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

  • emergency use authorization approved

    Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

  • FDA clears text

    Vetex Medical’s Thrombectomy Catheter Cleared by FDA

  • 100Bills_flatmoney.gif

    Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing